JPM前瞻 | 8个临床二期阶段的抗体/多肽药物项目汹涌来袭！
China Focus是由美柏医健（MyBioGate）发起并主办，中美生物医药创新中心（CUBIO），艾美达联合主办，以聚焦中国为特色，采用“一对一”项目对接为主要形式的系列对接论坛。
2019年1月6日，在三番市举办的China Focus@JPM Week将以“聚焦中国、全球合作、早期参与、精准对接”为主题，不仅将筛选150+以临床前到临床二期为主，可以进行中国市场权益合作的全球创新产品，也可以为参会中国企业提供定制化的项目对接服务。
来参加JPM的都有哪些项目呢，今天我们先来介绍处于临床二期阶段的8个抗体/多肽药物。我们在前线的同事也会陆续整理更多的好项目给大家。
1
药物类型：蛋白质药物
2
适应症：Obesity
3
临床阶段：临床二期
4
作用机制：G蛋白偶联受体调节因子
5
Target audience：Investors
6
参会目的：Develop through commercialization, or partner with large pharma
1
药物类型：多肽药物
2
适应症：高原肺水肿
3
临床阶段：临床二期
4
作用机制：离子通道调节因子，非类固醇类抗炎药物
5
Target audience：Biotech / Pharma Industry
6
参会目的：offers partnering agreements to interested regional / global pharmaceutical organisations.
7
项目亮点：现在市场上没有能治疗高原肺水肿的药物。公司071 received orphan drug designation for various life-threatening pulmonary indications by FDA and EMA。
1
药物类型：多肽药物
2
适应症：Acute decompensated heart failure
3
参会目的：License or partner or start-up
4
项目亮点：Mayo Clinic 合作研发
1
药物类型：蛋白质药物
2
适应症：Neoplasm, Ovary disease, Ovary tumor, Lymphoma, Solid tumor
3
临床阶段：临床二期
4
作用机制：
stimulates the immune system to produce T cell responses targeting the tumor associated antigen survivin
5
项目亮点：肿瘤免疫疗法，广谱肿瘤疫苗
1
药物类型：单抗药物
2
适应症：移植排斥, Graft versus host disease
3
临床阶段：临床二期
4
作用机制：Immunomodulator, Immunotoxin
5
项目亮点：designated orphan product (both in the US & EU) that is being developed for treating steroid-resistant acute Graft-vs-Host Disease (SR-aGVHD). 已经完成的的phase 1/2期已经显示出可喜的疗效。Based on the regulatory advice obtained from both the FDA and EMA, the next study could be a pivotal study qualifying for market approval.
6
Target audience：
Pharmaceutical distribution companies, clinical development partners, life science investors
1
药物类型：抗体药物
2
临床阶段：临床二期
3
作用机制：anti-RANK/RANKL recombinant fusion protein with a mechanism of action similar to Denosumab
4
参会目的：Product is available for partnering outside of Russia / CIS, Turkey / MENA
5
项目亮点：Phase I in Australia and Phase IIa in Russia recently completed with encouraging PD/biomarkers results.
1
药物类型：抗体药物
2
适应症：Metastatic non small cell lung cancer
3
临床阶段：临床二期
4
作用机制：a biosimilar of Avastin®, Roche with high expression level and analytical parameters close to the original product
5
参会目的：interested in product out- licensing outside of Russia/CIS
6
项目亮点：在临床一期中，compared to Avastin®, Roche, in combination with paclitaxel+carboplatin chemotherapy in patients with advanced inoperable or metastatic non-squamous non-small cell lung cancer.
1
药物类型：抗体药物
2
适应症：Immune disorder, Inflammatory disease, Metabolic disorder
3
临床阶段：临床二期
4
作用机制：Immunomodulator, an alpha1-proteinase inhibitor that is indicated for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (Alpha1-PI)
5
参会目的：License or co development partner for T1D indication outside of United States, Canada, Australia, and New Zealand
好了，以上就是今天8个项目的简述了。
<—选择意向项目，获取项目更详尽的信息
如果您对项目有疑问，请你联系美柏医健中国区负责人：
联系人｜戴有文
电 话｜15151852853（同WeChat）
长按二维码联系我们
文章版权归【美柏医健】所有
欢迎转发，转载请参照“转载须知”
投稿或应聘，请将简历发送到
精选内容
最新评论
推荐文章
作者最新文章
你可能感兴趣的文章
Copyright Disclaimer: The copyright of contents (including texts, images, videos and audios) posted above belong to the User who shared or the third-party website which the User shared from. If you found your copyright have been infringed, please send a DMCA takedown notice to [email protected]. For more detail of the source, please click on the button "Read Original Post" below. For other communications, please send to [email protected].
版权声明：以上内容为用户推荐收藏至CareerEngine平台，其内容（含文字、图片、视频、音频等）及知识版权均属用户或用户转发自的第三方网站，如涉嫌侵权，请通知[email protected]进行信息删除。如需查看信息来源，请点击“查看原文”。如需洽谈其它事宜，请联系[email protected]。
版权声明：以上内容为用户推荐收藏至CareerEngine平台，其内容（含文字、图片、视频、音频等）及知识版权均属用户或用户转发自的第三方网站，如涉嫌侵权，请通知[email protected]进行信息删除。如需查看信息来源，请点击“查看原文”。如需洽谈其它事宜，请联系[email protected]。